<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868933</url>
  </required_header>
  <id_info>
    <org_study_id>NAFLD-Diet</org_study_id>
    <nct_id>NCT00868933</nct_id>
  </id_info>
  <brief_title>Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease - A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <brief_summary>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in affluent
      countries. It may progress to cirrhosis and liver cancer. At present, there is no approved
      drug for NAFLD. Although healthy diet and exercise is often recommended, there is little
      supportive evidence. Therefore, the investigators plan to conduct a randomized controlled
      trial comparing a low glycemic index dietary intervention program and simple lifestyle advice
      in NAFLD patients. The primary endpoint is resolution of NAFLD. Non-invasive tests will be
      used to assess the study subjects. Proton-magnetic resonance spectroscopy is used to quantify
      hepatic triglyceride content, and transient elastography is used to quantify liver fibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of NAFLD by proton-magnetic resonance spectroscopy</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial resolution of NAFLD</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral fat measurement</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fibrosis by transient elastography</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic endpoints</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Low glycemic index dietary intervention program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simple lifestyle advice</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low glycemic index dietary intervention program</intervention_name>
    <description>The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.</description>
    <arm_group_label>Low glycemic index dietary intervention program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>simple lifestyle advice</intervention_name>
    <description>The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.</description>
    <arm_group_label>Simple lifestyle advice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 70 years

          -  Fatty liver by proton-magnetic resonance spectroscopy, defined as hepatic triglyceride
             content 5% or above

          -  Serum alanine aminotransferase (ALT) above 30 U/L in men and 19 U/L in women

          -  Informed written consent obtained

        Exclusion Criteria:

          -  Positive hepatitis B surface antigen, anti-hepatitis C virus antibody, or anti-nuclear
             antibody titer above 1/160

          -  Alcohol consumption above 30 g per week in men or 20 g per week in women

          -  Alanine aminotransferase (ALT) above 10 times the upper limit of normal

          -  Liver decompensation, as evidenced by bilirubin above 50 µmol/l, platelet count below
             100 × 10e9/l, prothrombin time above 1.3 times the upper limit of normal, albumin
             below 35 g/l, presence of ascites or varices

          -  Evidence of hepatocellular carcinoma

          -  Terminal illness or cancer, unless in complete remission for more than 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong SAR</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112. Review.</citation>
    <PMID>16447287</PMID>
  </reference>
  <reference>
    <citation>Wong VW, Chan HL, Hui AY, Chan KF, Liew CT, Chan FK, Sung JJ. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol Ther. 2004 Jul 1;20(1):45-9.</citation>
    <PMID>15225170</PMID>
  </reference>
  <reference>
    <citation>Wong VW, Wong GL, Chim AM, Tse AM, Tsang SW, Hui AY, Choi PC, Chan AW, So WY, Chan FK, Sung JJ, Chan HL. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 2008 Jul;103(7):1682-8. doi: 10.1111/j.1572-0241.2008.01933.x. Epub 2008 Jul 4.</citation>
    <PMID>18616651</PMID>
  </reference>
  <reference>
    <citation>Hui AY, Wong VW, Chan HL, Liew CT, Chan JL, Chan FK, Sung JJ. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther. 2005 Feb 15;21(4):407-13.</citation>
    <PMID>15709991</PMID>
  </reference>
  <reference>
    <citation>Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999 Mar;29(3):664-9.</citation>
    <PMID>10051466</PMID>
  </reference>
  <reference>
    <citation>Wong VW, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, So WY, Cheng AY, Ng WF, Wong GL, Sung JJ, Chan HL. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006 Sep;4(9):1154-61. Epub 2006 Aug 14.</citation>
    <PMID>16904946</PMID>
  </reference>
  <reference>
    <citation>Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007 Aug;30(8):2119-21. Epub 2007 May 22.</citation>
    <PMID>17519430</PMID>
  </reference>
  <reference>
    <citation>Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, So WY, Cheng AY, Tong PC, Chan FK, Sung JJ, Chan HL. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006 Oct 15;24(8):1215-22.</citation>
    <PMID>17014580</PMID>
  </reference>
  <reference>
    <citation>Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006 Nov 30;355(22):2297-307.</citation>
    <PMID>17135584</PMID>
  </reference>
  <reference>
    <citation>Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21. Erratum in: N Engl J Med. 2007 Jul 5;357(1):100..</citation>
    <PMID>17517853</PMID>
  </reference>
  <reference>
    <citation>Chan HL, de Silva HJ, Leung NW, Lim SG, Farrell GC; Asia-Pacific Working Party on NAFLD. How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol. 2007 Jun;22(6):801-8. Review.</citation>
    <PMID>17565632</PMID>
  </reference>
  <reference>
    <citation>Chan HL, Wong VW. Can dietetic intervention for obesity ever succeed in real life? J Gastroenterol Hepatol. 2007 Apr;22(4):459-60.</citation>
    <PMID>17376032</PMID>
  </reference>
  <reference>
    <citation>Ludwig DS. Clinical update: the low-glycaemic-index diet. Lancet. 2007 Mar 17;369(9565):890-2. Review.</citation>
    <PMID>17368136</PMID>
  </reference>
  <reference>
    <citation>Woo J, Sea MM, Tong P, Ko GT, Lee Z, Chan J, Chow FC. Effectiveness of a lifestyle modification programme in weight maintenance in obese subjects after cessation of treatment with Orlistat. J Eval Clin Pract. 2007 Dec;13(6):853-9.</citation>
    <PMID>18070255</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>February 20, 2014</last_update_submitted>
  <last_update_submitted_qc>February 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Henry LY Chan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

